MENU
ALGS
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Aligos Therapeutics (ALGS) Ownership - Who owns Aligos Therapeutics?
Profile
Industry
N/A
Address
One Corporate Drive
Phone
+1 800 466-6059
Employees
66
Web
https://www.aligos.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
123.67M
P/E Ratio
N/A
Total Cash
74.92M
Projected Growth
N/A
Total Debt
9.13M
Revenue
6M
Risk (Beta)
2.12
Dividend Yield
N/A
Total Cash/Share
20.88
Total Debt/Equity
N/A
Revenue/Share
1.00 USD as % of share price
Fundamentals
ALGS
Capitalization
124M
P/E Ratio
N/A
Risk (Beta)
2.12
Dividend Yield
N/A
Total Cash
74.9M
Total Cash/Share
20.88
Total Debt
9.13M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
1.00%
Revenue
6M
ROE
N/A
Book Value
50.1M
P/B Ratio
2.47
Cash Flow
N/A
Earnings
-7.25
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
8K
Current Ratio
3.81
Current Revenue Per Employee
18661.77
Dividends Per Share - Security
N/A
EBITDA
-91.86M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-88.31
Shares Held By Institutions
16.3M
Shares Outstanding - Current
3.59M
Total Liabilities
38.3M
Total Volume MTD
N/A
Value
N/A
Gain YTD
107.651
View a ticker or compare two or three
VS
VS
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
Industry Biotechnology
Profile
Fundamentals
Details
Industry
N/A
Address
One Corporate Drive
Phone
+1 800 466-6059
Employees
66
Web
https://www.aligos.com